Phase I/II Thymus Transplantation With Immunosuppression #950
Public ClinicalTrials.gov record NCT00579527. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II Trial of Thymus Transplantation With Immunosuppression, #950
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study purpose is to determine if cultured thymus tissue implantation (CTTI) (previously described as transplantation) with tailored immunosuppression based on the recipient's pre-implantation T cell population is a safe and effective treatment for complete DiGeorge anomaly. This study will also evaluate whether cultured thymus tissue implantation and parathyroid transplantation with immunosuppression is a safe and effective treatment for complete DiGeorge anomaly and hypoparathyroidism.
Study identification
- NCT ID
- NCT00579527
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 14 participants
Conditions and interventions
Conditions
Interventions
- Cultured Thymus Tissue for Implantation (CTTI) Biological
- Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation Other
- Blood Draw Procedure
- Rabbit anti-thymocyte globulin Drug
- Cyclosporine Drug
- Tacrolimus Drug
- Methylprednisolone or Prednisolone Drug
- Daclizumab Drug
- Mycophenolate mofetil Drug
Biological · Other · Procedure + 1 more
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 18, 2005
- Primary completion
- Nov 30, 2011
- Completion
- Dec 30, 2017
- Last update posted
- Mar 24, 2022
2005 – 2017
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00579527, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 24, 2022 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00579527 live on ClinicalTrials.gov.